The German economy is undergoing a period of upheaval. The automotive industry is
investing billions in developing new powertrain technologies and mobility services, while
manufacturing industries and mechanical engineering are becoming greener and more
sustainable. Following the phase-out of nuclear power, by 2038 brown coal will no longer be used
for electricity generation and priority is being given to developing renewable energy sources.
And importantly, digitalization is making its way into almost all areas of our lives. And as if all of this weren’t exciting enough, 2020 will go down in history as the year of the coronavirus pandemic. The virus is not only putting businesses and jobs at risk, it is also speeding up some development processes.
MEDICAL TECHNOLOGY AND PHARMACEUTICALS IN SAXONY-ANHALTMedicaltechnology andpharmaceuticalsinSaxony-AnhaltExperiencepaves the wayIDT Biologika from Dessauis carrying out research into acoronavirus vaccine.Expertise andexperience:IDT Biologikaemploys 1500people at theBioPharma-Park Dessau.Health relies on more than justgood luck. Surgical robots, imagingprocesses and intelligentcatheters are just some of thelatest medical systems to be producedin Saxony-Anhalt. Highlyinnovative companies from thepharmaceutical and biotechindustries form a strong clusterhere. In cooperation with universitiesand research institutions,they are developing new and improveddiagnostic and therapeuticmethods.invest-in-saxony-anhalt.comThe process of having a new vaccineapproved normally takes several years. Butin the midst of the coronavirus pandemic, wedo not have this much time to play with. Researchersall over the world are putting everyeffort into finding a vaccine for the SARS-CoV-2 virus. This is the top priority for IDTBiologika, a company based in Dessau-Roßlau.The compounds produced by IDT have beenhelping in the fight against diseases and epidemicsfor several years.IDT Biologika is now one of the leading playersin the search for a coronavirus vaccine. Thecompany is working closely with the GermanCenter for Infection Research and with partnersat the Universities of Munich and Marburgto develop a vector vaccine. This involvesinserting genetic information from a surfaceprotein of the coronavirus into a harmless carriervirus that will not cause a disease but willstimulate the immune system into producingantibodies.“We can build on a system thathas been clinically tested for20 years. We know that thevaccine is effective in animaltests and that we are on theright track. But we don’t yetknow if it protects people andprovides the required level ofimmunity,”explains Dr Andreas Neubert, head of researchand development at IDT Biologika.3233